GSK And HGS Face Off Over Buyout
This article was originally published in The Pink Sheet Daily
Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.
You may also be interested in...
HGSI Gets Slightly Increased Buyout Bid, Accepts GSK Offer Of $3.6 Billion
After three months of battling, with lupus drug Benlysta still struggling, Human Genome Sciences accepted a modestly increased sales offer from partner GlaxoSmithKline.
Financings Of The Fortnight Parses Federal Funding For Roche/Genentech Alzheimer’s Candidate
Plus news on recent financing activity by Arena, OncoMed, Egalet and Dynavax.
Deals Of The Week: GSK/HGSI, Daiichi Sankyo/Coherus
GSK/Human Genome story takes a sharp turn, but does the big pharma’s hostile bid expose greater interest in cardiovascular drug darapladib than it is admitting?